Axogen said it will buy privately held Biocircuit Technologies for $200 million in cash, adding Nervetape, the first FDA-approved device for sutureless peripheral nerve repair, to its portfolio.
The deal is expected to close in the fourth quarter of 2026, pending customary closing conditions and the spin-out of Biocircuit’s electronics research and development business. At closing, $1 million of the estimated consideration will be withheld until the post-closing purchase price adjustment is determined.
Axogen said the acquisition is expected to be accretive to revenue growth, adjusted EBITDA margin and adjusted earnings per share in the first year after closing, while the company remains free cash flow positive.
The company said Nervetape broadens its addressable market within its focus markets by reducing dependence on microsurgical skills and making nerve repair simpler and faster. Axogen said the device has already been adopted by surgeons across multiple nerve repair settings and that its sales force, surgeon relationships and hospital contracting network should accelerate adoption.
Management also said the deal adds a foundational technology platform that could support future product development and expansion into new indications. Today the company's shares have moved -10.63% to a price of $42.245. If you want to know more, read the company's complete 8-K report here.
